On behalf of the Executive Committee of the International College of Neuropsychopharmacology (CINP) and our partner organization, the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN), it is my pleasure to invite you to the 33rd CINP World Congress of Neuropharmacology.
Due to the continued global presence of COVID-19 and the uncertainty for large gatherings, international travel and being granted leave, the CINP World Congress will be delivered in a hybrid format, with a mixture of in-person presentations in Taipei, Taiwan and virtual presentations from those who are unable to travel to Taiwan in June 2022.
This upcoming World Congress welcomes delegates from all over the globe to join us virtually or in the beautiful city of Taipei to carry on the momentum of the previous World Congresses. Building on our previous efforts, we will expand our core mission of linking the advances in brain sciences to the alleviation of the distress and disabilities associated with neuropsychiatric disorders. With advances in neuroscience, this is an exciting time for the understanding of psychiatric pathophysiology and the 33rd CINP Hybrid World Congress will feature the most up-to-date research, diverse topics of interest, and educational sessions with leading experts.
We hope that you will be able to join us to advance the research and education of psychopharmacology.
Professor Pierre Blier
CINP President (2021-2022)
The International College of Neuropsychopharmacology (CINP) (Collegium Internationale Neuro-Psychopharmacologicum) is a truly worldwide organizations established over 60 years ago in Zurich, Switzerland and can count on a widespread support from all over the world by its active members. Holding regular meetings in form of Training, Educational Programs, International Meetings and World Congresses, CINP reaches interested researchers all over the world. Clinicians hear about the latest research advances and new treatments whilst researchers hear about new clinical needs and problems. Therefore, CINP is dedicated to promoting research and education on a worldwide basis.
To encourage and promote international scientific study, teaching and the application of neuropsychopharmacology.
The College relies on its many subcommittees who undertake a variety of activities for CINP and are dedicated to developing the many different facets of CINP activity. For example, two of the remits of our Education Committee are to bring neuropsychopharmacology to colleagues in developing regions and to develop and deliver the active mentor-mentee program.
Its membership includes psychiatrists, pharmacologists and other basic scientists, and research psychologists and is available to any individual to apply for. The membership application is reviewed by the dedicated committee on a regular basis.
The CINP 2022 program will start on June 9, 2022, at 9:15 am (Taiwan Time, GMT+8). The virtual platform will open on June 5, 2022, to allow advanced exploration of the virtual space. A link to the platform will be provided on June 5, 2022. Please keep an eye out for incoming messages from “Pheedloop” in the email account you used for registration. If you do not receive the email with the virtual platform link, please check your spam/junk folder.
Log in with your registration email address and the password provided in your CINP 2022 Virtual Event Portal Access email sent to you.
Once you are logged in, you can update your profile and select the visibility of your profile by clicking on the “Account” tab.
We strongly recommend using a modern browser to participate in the virtual event. Specifically, we suggest Google Chrome for its security and feature compatibility.
A high-speed internet connection is recommended to participate in sessions without experiencing interruptions. If the stream is working, but the audio or video seems choppy, it is possible your internet connection is too slow, unstable, or bandwidth is being utilized elsewhere.
I Can See The Video, But I Do Not Have Sound
Ensure your speakers are not muted, none of the controls on the stream (if available) are muted, and no other tab is occupying your audio channel.
I Am Having Audio Issues
Please make sure you clicked on “Join Computer Audio” on the session screen when it opens. You may also re-click on the session name (left side) to refresh the stream (DO NOT refresh your browser; this will cause you to log out of the session). If your sound issue continues, please exit, and re-enter the meeting. During live broadcast hours, you can also connect with us via the LiveChat in the bottom left corner of our screen. If you are watching presentations on tablet/ phone, you may consider using a headset.
Enter a full-screen mode for the best presentation experience – click “Full Screen” (top right corner of the presentation screen).
The presentations will be recorded and made available on the platform shortly after the live broadcast and will be available for on-demand viewing for three months following the Congress.
For the best experience, we recommend at least 1.2 Mbps download speed.
Unfortunately, no. You will require a high-speed internet connection to stream the presentations.
To reach CINP 2022 Secretariat, please email CINP2022email@example.com.
Psych Congress Europe (Postponed)
ESCAP 19th International Congress 2022
19-21 June 2022
The ESCAP 19th International Congress 2022 will be held in Maastricht - in the south of The Netherlands, close to the German and Belgian borders - under the responsibility of the Dutch ESCAP member: the child and adolescent faculty of the NVvP, the Dutch Association for Child and Adolescent Psychiatry. The ESCAP 2022 Congress theme in Maastricht will be: ‘Networks in Child and Adolescent Psychiatry’. The congress brings together psychiatrists, psychologists and other youth mental health professionals from different European countries to meet and exchange scientific knowledge and practice-based information.
2022 ASCP Annual Meeting
May 31 – June 03, 2022
The 2022 Annual Meeting of the American Society of Clinical Psychopharmacology (formerly NCDEU) will take place at the Fairmont Scottsdale Princess in Scottsdale, Arizona from May 31 – June 03, 2022. The meeting will include representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry discussing key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on based on biomarkers or genetic information. The theme for the ASCP 2022 Annual Meeting is Reassessing Research and Clinical Practice in the Peri-pandemic Era. Early Bird registration ends on March 31st. Please CLICK HERE for more information and to register!
22nd WPA World Congress of Psychiatry
3-6 August 2022
2022 World Neuroscience and Psychiatry Conference (2022WNPC)
September 9-10, 2022
DGPPN Congress 2022
November 23-26, 2022
cinp-congress at cinp.org
cinp2022-program at cinp.org
Sponsorship & Exhibit Sales Manager
sponsorship at cinp.org
Registration & Housing Manager
cinp2022-registration at cinp.org
CINP Association Manager
info at cinp.org
International Conference Services LTD (ICS)
Suite 710, 1201 West Pender Street
Vancouver, BC, Canada V6E 2V2
Phone: +1 604-681-2153
Fax: +1 604-681-1089
ICS Europe – Vienna
Nußdorfer Straße 20/22
1090 Vienna, Austria
View CINP 2022 Program
This program is a preliminary version and is subject to change without notice. The official time zone for CINP 2022 is in Taiwan Time (GMT+8).
Title: Immunopsychiatry After COVID-19
Details: Thursday, June 9, 15:45 - 16:45 (GMT+8)
Speaker: Prof. Francesco Benedetti, University Vita-Salute San Raffaele, Milano
Chair: Prof. Pierre Blier, University of Ottawa Institute of Mental Health Research, Canada
Description: Immunopsychiatry can be defined as the study of immune-inflammatory pathways in order to identify pathogenetic mechanisms, and targets for treatment in psychiatric conditions. We can affirm that COVID-19 survivors show persistent psychopathology and neurocognitive impairment in around 35% of patients. The cluster of Post-Acute Sequelae of COVID-19 (PASC) symptoms typically emerge after the acute phase of illness, when patients are no longer positive to SARS-CoV-2, including dyspnoea, hypoxia, joint and muscle pain, paraesthesia, dysgeusia, anosmia, fatigue. Unrelated to the latter, there are symptoms of depression, anxiety, insomnia, difficulties in sustained attention and memory, which worsen over the months. Brain correlates involve diffuse disruption of white matter microstructure, reduced grey matter volumes in anterior cingulate cortex, and abnormal functional connectivity in the cortico-limbic circuitries. These are proportional to the degree of persistent systemic inflammation, but not to the severity of the acute illness and the breadth of exposure to stressful events during the pandemic. We suggest that post-COVID depression provides an invaluable model illness for the study of immune-inflammatory mechanisms involved in the pathogenesis of mood disorders to identify new targets to restore mental health and brain homeostasis.
Title: Deciphering the Mystery of Sleep: Toward the Molecular Substrate for “Sleepiness”
Details: Friday, June 10, 6:15 - 7:15 (GMT+8)
Speaker: Prof. Masashi Yanagisawa, The University of Tsukuba, Japan
Chair: Prof. Noriko Osumi, Tohoku University, Japan
Description: Although sleep is a ubiquitous behavior in animal species with central nervous systems, the neurobiology of sleep remain mysterious. Our discovery of orexin, a hypothalamic neuropeptide involved in the maintenance of wakefulness, has helped reveal neural pathways in the regulation of sleep/wakefulness. Orexin receptor antagonists, which specifically block the endogenous waking system, have been approved as a new drug to treat insomnia. Also, since the sleep disorder narcolepsy-cataplexy is caused by orexin deficiency, orexin receptor agonists are expected to provide mechanistic therapy for narcolepsy; they will likely be also useful for treating excessive sleepiness due to other etiologies.
Despite the fact that the executive neurocircuitry and neurochemistry for sleep/wake switching has been increasingly revealed in recent years, the mechanism for homeostatic regulation of sleep, as well as the neural substrate for “sleepiness” (sleep need), remains unknown. To crack open this black box, we have initiated a large-scale forward genetic screen of sleep/wake phenotype in mice based on true somnographic (EEG/EMG) measurements. We have so far screened >10,000 heterozygous ENU-mutagenized founders and established a number of pedigrees exhibiting heritable and specific sleep/wake abnormalities. By combining linkage analysis and the next-generation whole exome sequencing, we have molecularly identified and verified the causal mutations in several of these pedigrees. Biochemical and neurophysiological analyses of these mutations are underway. Indeed, through a systematic cross-comparison of the Sleepy mutants (with a gain-of-function change in a serine/threonine kinase pathway) and sleep-deprived mice, we have found that the cumulative phosphorylation state of a specific set of mostly synaptic proteins may be the molecular substrate of sleep need.
Title: Absolutely on Mental Health: Conversations between Audrey Tang and Pierre Blier
Details: Friday, June 10, 15:15 - 16:15 (GMT+8)
Chair: Prof. Kazutaka Ikeda, Tokyo Metropolitan Institute of Medical Science, Japan
Description: As a world-renowned genius and the world’s first nonbinary and openly transgender cabinet member, Taiwan’s Digital Minister Audrey Tang successfully applies the technology in the COVID-19 prevention in Taiwan. She develops digital social innovation tools to help Taiwan health and disease control government officials efficiently and quickly track and control the spread of the virus. At the 33rd CINP world congress of neuropsychopharmacology, Minister Tang will have a brilliant conversation with CINP President Professor Pierre Blier. Topics will include the application of technology in mental health, the digital psychiatry, and the next-generation psychiatry in a virtual world. Let’s join them together online and in Taipei.
Details: Saturday, June 11, 14:30 - 15:30 (GMT+8)
Speaker: Dr. Hailan Hu, Zhejiang University, China
Chair: Prof. Gabriella Gobbi, McGill University, Montreal, Canada
Description: Ketamine, the N-methyl-D-aspartate receptor (NMDAR) antagonist, has revolutionized depression treatment because of its robust, rapid and sustained antidepressant effects. Recently, it was discovered that ketamine inhibits the NMDAR-dependent burst firing of the brain’s anti-reward center, the lateral habenula (LHb). By silencing the LHb bursts, ketamine can disinhibit the aminergic reward circuits downstream of LHb to exert its rapid antidepressant effects.
However, at least three key questions have remained unaddressed. Firstly, does blockade of LHb burst firing contribute to ketamine’s sustained antidepressant effects? Despite of its rapid metabolic half-life (3 h in human and 13 min in mice), the antidepressant effects of a single application of ketamine can last for 3～14 d in humans and for at least 24 h in mouse models of depression. It will be clinically important to understand to what extent ketamine’s local action in the LHb contributes to its sustained effects. Secondly, given that NMDARs are ubiquitously expressed, which specific brain region is the direct target of ketamine? It will be important to distinguish the primary versus the secondary targets. Thirdly, will a drug targeting the same cellular/circuit mechanism of ketamine have similar antidepressant effects? More specifically, since LHb burst firing requires the synergistic action of both NMDARs and the T-type calcium channel (T-VSCC), can T-VSCC inhibitors be antidepressant?
In this talk, I will present our ongoing efforts in addressing these three urgent questions, which will hopefully illuminate a unified theory on ketamine’s mode of action and inspire new treatment strategies for depression.
Title: Inflammation and Depression: Questions of Causality
Details: Saturday, June 11, 19:45 - 20:45 (GMT+8)
Speaker: Dr. Edward Bullmore, University of Cambridge, United Kingdom
Chair: Dr. John Krystal, Yale School of Medicine, USA
Description: Inflammation is robustly associated with depression and other mental health disorders. However, there are many open questions about the causal relationships that might explain the increasing mass of largely correlational findings. I will review several approaches to causality in the context of human research, including neuroimaging studies, meta-analyses of anti-depressant effects of anti-inflammatory drugs, and epigenetic activation of GWAS variants for risks of mental health disorders. I will also explore the hypothetical model that early life adversity and other social stressors could perturb developmental trajectories of the central nervous system and the peripheral immune system, leading to long-term changes in vulnerability to depression and other health disorders in adult life.
Details: Sunday, June 12, 21:00 - 22:00 (GMT+8)
Speaker: Dr. Serena Pudich, Yale University, United States
Chair: Dr. John Krystal, Yale School of Medicine, USA
During acute COVID-19, patients can experience ischemic cerebrovascular disorders, encephalopathy, and prolonged unconsciousness and altered mental states, including psychosis and delirium. Some individuals also develop a loss of smell and taste, myalgias and fatigue, or neuromuscular disorders. Many patients also experience post-acute COVID neurologic and psychiatric issues. These include prolonged symptoms of fatigue, memory concentration disorder, headache, pain, insomnia, anxiety, and depression.
Aims & Objectives
This talk will cover neurologic reports in acute COVID-19, existing knowledge regarding acute COVID-19 neuropathogenesis, and describe the clinical syndromes and explore potential mechanisms of nervous system Long COVID.
The speaker will review and critically interpret existing published literature. She will also draw upon her clinical observations and experiences caring for patients with COVID-19 and acute or lingering nervous system consequences. Finally, she will present unpublished data from her group’s investigation into the pathophysiology of Long COVID.
At the end of the talk, the audience should be able to identify the clinical and pathophysiologic effects of SARS-CoV-2 in the nervous system during acute COVID-19, focusing on immunopathogenesis and neuronal injury. The audience will also be able to describe the hypotheses regarding potential underlying mechanisms of nervous system Long COVID, or post-acute sequelae of COVID-19, and recognize that lingering nervous system effects can occur in patients who experienced mild forms of COVID-19.
The presentation will conclude with a discussion of future research gaps and priorities particularly with regard to long term neurologic and neuropsychiatric complications post-COVID-19.
Details: Monday, June 13, 3:30 - 4:30 (GMT+8)
Speaker: Dr. Tom Insel, National Institutes of Health, United States
Chair: Prof. Joseph Zohar, Chaim Sheba Medical Center, Israel
Description: Most of us have embarked on careers in neuropharmacology because we want to develop better treatments for people with mental illness and ultimately contribute to public health. Arguably the last five decades have been a golden era for neuropharmacology with a broad range of compounds (as well as psychological and neuromodulatory interventions) developed for mood, anxiety, and psychotic disorders. With so much progress in science, why have we made so little progress in outcomes for people with mental illness, especially those with serious mental illness? Why have we failed to reduce death and disability? Our usual explanations (lack of treatments, lack of knowledge, lack of providers, stigma) are not sufficient answers to this question. We face a mental health crisis not from a failure of research or insufficient workforce but from a broken mental health care system. Fixing the care system through better engagement, quality, and accountability will provide more immediate solutions, including some that can be delivered via technology. In 2022, we can achieve better outcomes from better care, using the treatments we have today. But to close the outcome gap, we need to understand that mental health is not simply a product of mental health care. Indeed, health care explains a relatively small fraction of health outcomes. This presentation will reframe the mental health crisis as more than a healthcare crisis, reminding us that we will always need better treatments but our immediate call to action is to use the treatments we have more effectively.
Title: ENCP Meet the Expert NbN
Details: Friday, June 10, 10:45 - 11:45 (GMT+8)
Speaker: Prof. Joseph Zohar, Chaim Sheba Medical Center, Israel
Description: The current disease-based nomenclature of psychotropics medications does not reflect contemporary knowledge, nor does it appropriately inform the clinician about rational neuroscience-based prescribing. Moreover, it is confusing for the patients as very often we prescribe “antidepressants” for anxiety disorders or “second-generation antipsychotics” to depressed patients who show no evidence of psychosis. Five major international neuropsychopharmacological scientific organizations joined forces together, in 2008, to create new nomenclature. These organizations are: ECNP, ACNP, AsCNP, CINP and IUPHAR.
The mission was:
- To provide a pharmacologically-driven (rather than indication-based nomenclature).
- To expand our toolbox by pointing out the relevant mechanism (via pharmacology and mode of action).
- To help clinicians to make informed choices when they are trying to figure out what would be the next “pharmacological step”.
- To decrease stigma and enhance adherence by a naming system that lays out the rationale for selecting a specific psychotropic.
Currently, NbN has been downloaded close to 100,000 psychiatrists worldwide and has been endorsed by many organizations including APA, EPA, DGPPN, JSPN, and SEP to name a few. It is also a part of major textbook of psychiatry including Oxford textbook of psychiatry, the next edition of Kaplan & Sadock textbook of psychiatry and more. NbN reflects current knowledge and understanding about the targeted neurotransmitters/molecules/system being modified + mode/ mechanism of action and includes 147 compounds that cover the vast majority of psychotropics used worldwide. In this session we will explain the concept and will do live presentation of NbN apps. (IOS: NbN3, NbNca ; Android: NbN3, NbNca).
Details: Saturday, June 11, 13:15 - 14:15 (GMT+8)
Speaker: Prof. Tung Ping Su, Department of Psychiatry, Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan
Description: Professor Tung-Ping Su has devoted himself to the treatment and research of treatment-resistant depression (TRD) since he returned to Taiwan from the NIMH in the United States in 1996. In Taiwan, he completed the first randomized, double-blind, sham-controlled trial of rTMS in patients with TRD in 2005. He further completed the first randomized, double-blind, placebo-controlled trial of low-dose ketamine infusion in patients with TRD in 2017. His clinical and research career represents the history of novel treatments for TRD in Taiwan. Today, he will talk about the past, present and future of TRD treatment.
Details: Monday, June 13, 00:15 - 01:15 (GMT+8)
Speaker: Prof. Pierre Blier, University of Ottawa Institute of Mental Health Research, Canada
Description: In this workshop, participants will be presented with the various medications that can be used and how to choose the potentially most useful and better-tolerated ones for specific patients. The main interactions with other medications used to treat co-morbidities will be described. Emphasis will be concentrated on cases of treatment resistance and how to devise comprehensive treatment plans. Participants will be encouraged throughout to ask questions and volunteer cases they are currently having difficulties to manage.
The CINP International Scientific Programme Committee is pleased to announce the following plenary speakers for the 2022 CINP Hybrid World Congress.
MINISTER AUDREY TANG
DIGITAL MINISTER, TAIWAN
DR. EDWARD BULLMORE
PROFESSOR OF PSYCHIATRY AND CLINICAL DIRECTOR, BEHAVIOURAL & CLINICAL NEUROSCIENCE INSTITUTE, UNIVERSITY OF CAMBRIDGE, UNITED KINGDOM
PROF. FRANCESCO BENEDETTI
UNIVERSITY VITA-SALUTE SAN RAFFAELE, MILANO
DR. HAILAN HU
PROFESSOR AND DIRECTOR OF THE SCHOOL OF BRAIN SCIENCE AND BRAIN MEDICINE, ZHEJIANG UNIVERSITY, CHINA
PROF. MASASHI YANAGISAWA
THE UNIVERSITY OF TSUKUBA, JAPAN
DR. SERENA PUDICH
PROFESSOR OF NEUROLOGY AND CHIEF, DIVISION OF NEUROLOGICAL INFECTIONS AND GLOBAL NEUROLOGY, YALE UNIVERSITY, UNITED STATES
DR. TOM INSEL
NATIONAL INSTITUTES OF HEALTH, UNITED STATES
The CINP 2022 Hybrid World Congress will be an event that combines delivery, participation, and interaction for virtual and in-person audiences.
We can’t wait to meet with those who are able to travel to Taiwan at the conference venue between 9 - 13 June 2022. And by utilizing the latest technology to live-stream presentations to our virtual audience, we will provide opportunities for all attendees to engage with the scientific content, network with each other, and experience our first hybrid event.
Earn CME Accreditation at the 2022 CINP World Congress
We are pleased to announce that the 33rd CINP Hybrid World Congress of Neuropsychopharmacology, held from 9 to 13 June 2022 has been accredited by European Accreditation Committee in CNS (EACIC).
There will be a total number of 22 CME credits available for this congress.
How to Obtain CME Credits
Participants requesting CME credits are required to complete the online evaluation form on the EACIC website www.eacic.eu.
Please follow the below steps to receive your CME Certificate.
The deadline to complete the evaluation form is 13 September 2022.
If you have any enquiries, please contact firstname.lastname@example.org.
Download Presentation Slide Template
Download Background Option 1
Download Background Option 2
Download Background Option 3
Oral Presentation Upload (MP4 format only)
Poster Presentation upload (MP4 or PDF format only)
A link to upload your presentation or poster along with your final program number will be emailed to the presenting author by April 30, 2022. If you did not receive the link, please contact email@example.com.
Featured Oral Presentation
Important Technical Requirements
The Scientific Program Committee for the 33rd CINP World Congress of Neuropsychopharmacology (CINP 2022) thanks you for your submission of scientific abstracts.
If you have any questions regarding abstract submission, please contact the CINP Program Manager at cinp2022-program[at]cinp.org
Notification of abstract acceptance emails have gone out to all Presenting Authors. If you have not been contacted, please reach out to firstname.lastname@example.org.
Symposia of 90 min duration integrate the latest advances in basic, clinical, and translational neuropsychopharmacology, biological psychiatry, drug development public policy issues relevant to mental health, mental illness, and treatment across the lifespan.
Four Speakers including the Chairperson should represent at least three different countries and four different institutions. It is recommended that at least two speakers should be CINP members. Symposia proposals that include female faculty and investigators who obtained their last degree in the last 10 years are greatly encouraged.
The individual who submits the symposium proposal via the submission process below must be the Chairperson of their proposed session.
Submitters can apply for no more than two symposia and speakers can agree to participate in no more than two proposals.
CINP 2022 Symposia will be reviewed and selected on a highly competitive basis by the International Scientific Programme Committee in October 2021. Notifications will be sent to all symposia submitters in November 2021.
Speakers in successful symposia will receive the following entitlements:
For questions regarding the symposia submission, please contact CINP Program Manager at cinp2022-program[at]cinp.org
Stay tuned for more information on upcoming Congresses hosted by the International College of Neuropsychopharmacology (CINP).
International Conference Services LTD (ICS)
#710-1201 West Pender Street
Vancouver, BC, Canada V6E 2V2
Phone: [+1] 604-681-2153
Registration for In-Person Attendance Is Now Closed
Please note that in-person registration is only open to residents of Taiwan.
For non residents of Taiwan, please click HERE to register as a virtual attendee.
Residents of Taiwan who wish to attend the Congress in-person in Taipei, please visit the TSBPN website*. The in-person registration fee includes access to the live Virtual Congress and on-demand content up to 15 September 2022.
For inquiries regarding the in-person registration, please contact TSBPN at email@example.com.
CINP 2022 will be held at Chang Yung-Fa Foundation’s International Convention Center.
Address: No.11, Zhongshan S. Rd., Taipei City 10048, Taiwan (R.O.C.)
CHANG YUNG-FA FOUNDATION International Convention Center is located on Zhongshan South Road, an easily accessible thoroughfare. The building faces the Ketagalan Boulevard and is close to the National Taiwan University Hospital and Liberty Square (Chiang Kai-shek Memorial Hall). It is a 5min walk from MRT National Taiwan University Hospital Station and a 5min drive from Taipei Main Station.
Registration for CINP 2022 Virtual Library Now Closed
Virtual Library Registration Rates
Virtual Library Access Registration fee includes:
Access to On-Demand Content during the Congress and up to 15 September 2022
Eligibility for CINP Member Registration Fee
All CINP Members in good standing. Membership number will be required during the online registration process. If you do not know your membership number, please contact firstname.lastname@example.org.
Eligibility for Student/Trainee and Young Scientist Registration Fee
Proof of Status is required during the online registration process.
Student/Trainee - Please provide an official copy of your student card with photo or an official letter on your institution’s/organization’s letterhead that indicates proof of status as a Student or Trainee for 2022.
Young Scientist – Please provide an official copy of the last degree earned within the past 10 years.
If you are also a CINP Member, you will be required to provide your CINP membership number. If you do not know your membership number, please contact email@example.com.
Eligibility for Low and Lower-Middle Income Country Registration Fee
Residents of a country classified as “Low-Income” or “Lower-Middle Income” by the World Bank Classification as of 1 July 2021.
For groups of 10 or more registrations, please contact CINP2022firstname.lastname@example.org for assistance.
Registration fees are non-refundable; however, transfer of your registration to another person is acceptable. Please email CINP2022email@example.com. Deadline to transfer your registration is 20 May 2022.
Please check your email inbox for the Registration Confirmation. If not received, please check your spam folder before contacting CINP2022firstname.lastname@example.org for assistance.
For any CINP 2022 registration questions, please contact the Registration Manager at CINP2022email@example.com.
The Congress is pleased to offer a variety of opportunities, including but not limited to:
Past Event Attendance
Year Venue Attendance
2022 Taipei, Taiwan 1,500 exp.
2021 Virtual World Congress 743
2019 Athens, Greece 548
2018 Vienna, Austria 1,118
2016 Seoul, Republic of Korea 2,000
2014 Vancouver, Canada
Demographics & Statistics
Regional statistics from past CINP editions:
CINP 2022 (Taipei, Taiwan) CINP 2021 Virtual World Congress CINP 2019 (Athens, Greece) CINP 2018 (Vienna, Austria) CINP 2016 (Seoul, Republic of Korea)
10% North America
13% North America
1% South America
14% North America
1% South America
Top 5 countries
10% North America
Category statistics from CINP 2021:
Basic Researcher 14%
Clinical Researcher 12%
Child Psychiatrist 2%
Forensic Psychiatrist 1%
No. of Members: 542
North America 35%
Central & South America 3%
Area of Interest (Multiple Choice)
ffective disorder – Depression 63%
Affective disorder – Bipolar 45%
Anxiety Disorders 40%
Addiction & Substance Abuse 30%
Attention deficit/Hyperactivity disorders 6%
Parkinson’s & other degenerative diseases 15%
Please contact our Sponsorship and Exhibit Sales Managers to start discussing how you would like to support, and be involved in CINP 2022.
Sponsorship & Exhibit Sales Manager
Mrs. Tess Brown
sponsorship at cinp.org
Tess’s T: [+1] 604-681-2153 ext 176
International Conference Services Ltd. (ICS)
Suite 710, 1201 West Pender Street
Vancouver, BC, V6E 2V2
The following industry-supported symposia are organized by sponsors of the 33rd CINP World Congress of Neuropharmacology and will be available during the 2022 Live Days. Click on the tabs below to read more.
Introduction (5 mins)
The Challenge Anxiety Symptoms Treatment in Major Depressive Disorder (15 mins)
Evidence-based Pharmacotherapy of Anxiety Symptoms in Major Depressive Disorder (15 mins)
What do Patient want in the Treatment of Major Depressive Disorder? (Taiwan’s Tailor Survey) (15 mins)
Discussion and Closing (5 mins)
Professor Tung-Ping Su
Cheng Hsin General Hospital, Taiwan (R.O.C.)
Professor Dan J. Stein (Psychiatrist)
University of Cape Town, South Africa
Professor Malcolm Hopwood, (Prof of Psychiatry)
Albert Road Clinic, Australia
Professor Chia-Ming Chang
Chang Gung Memorial Hospital, Taiwan (R.O.C.)
Brief Description: This Janssen Asia Pacific symposium at the upcoming 33rd CINP Hybrid World Congress of Neuropsychopharmacology is one you would not want to miss! Presentations will shed light on the role of novel rapid-acting antidepressants in the management of major depressive disorder (MDD) with suicidal ideation (MDSI), a condition that represents a particularly vulnerable and hard-to-treat patient population which requires urgent treatment, and where current routine standard of care medications are inadequate. Our distinguished speakers will also share on their real-world experience, and discuss practicalities with the management of MDSI.
Opening remarks and introduction (5 mins)
A new era in the management of MDD with suicidal ideation (30 mins)
Management of MDD with suicidal ideation in Asia (15 mins)
Q&A; (10 mins)
Prof Cheng-Ta LI - Taiwan
National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Taipei, Taiwan
Prof Bernhard BAUNE - Germany
University Hospital of Psychiatry and Psychotherapy, University of Münster, Germany
The 33rd CINP World Congress of Neuropharmacology offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of neuropharmacology. The 33rd CINP World Congress of Neuropharmacology would like to thank the following companies for their support:
Session title: Cerevel Therapeutics Pipeline Overview
Session date and time: Thursday, June 9th, 10:45 - 11:00am (GMT+8)
Session brief description: Cerevel Therapeutics is advancing a broad and diverse neuroscience pipeline of small molecule therapies to address significant unmet medical needs and limited treatment options for patients suffering from some of the most prevalent neuroscience diseases. Dr. Takahashi will give an overview of our clinical pipeline comprised of multiple therapeutic candidates that have the potential to achieve optimal therapeutic activity while minimizing the unintended side effects of currently available therapies.
Speaker: Koji Takahashi, PhD. Sr. Director Medical Affairs, Cerevel Therapeutics, USA.
The 33rd CINP World Congress of Neuropharmacology offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of neuropharmacology. The 33rd CINP World Congress of Neuropharmacology would like to thank Sumitomo Pharma Co. Ltd & Sunovion Pharmaceuticals Inc for sponsoring these awards: